Last reviewed · How we verify
LOVAZA Omega 3-acid ethyl esters
LOVAZA reduces triglyceride levels by providing omega-3 fatty acids (EPA and DHA) that decrease hepatic triglyceride synthesis and increase triglyceride clearance.
LOVAZA reduces triglyceride levels by providing omega-3 fatty acids (EPA and DHA) that decrease hepatic triglyceride synthesis and increase triglyceride clearance. Used for Severe hypertriglyceridemia (≥500 mg/dL) as an adjunct to diet.
At a glance
| Generic name | LOVAZA Omega 3-acid ethyl esters |
|---|---|
| Also known as | Fish Oil, Lovaza |
| Sponsor | University of Michigan |
| Drug class | Omega-3 fatty acid supplement |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Omega-3 polyunsaturated fatty acids (EPA and DHA) work by inhibiting acyl-CoA synthetase and reducing the availability of precursors for triglyceride synthesis in the liver, while also enhancing the clearance of triglyceride-rich lipoproteins. This results in significant reductions in serum triglyceride concentrations, particularly in patients with severe hypertriglyceridemia.
Approved indications
- Severe hypertriglyceridemia (≥500 mg/dL) as an adjunct to diet
Common side effects
- Eructation (fish-flavored burps)
- Dyspepsia
- Nausea
- Increased bleeding tendency
Key clinical trials
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction (PHASE2)
- Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers (PHASE2)
- An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin (PHASE4)
- ASCEND: A Study of Cardiovascular Events iN Diabetes (PHASE4)
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (PHASE1, PHASE2)
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1, PHASE2)
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (PHASE1, PHASE2)
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LOVAZA Omega 3-acid ethyl esters CI brief — competitive landscape report
- LOVAZA Omega 3-acid ethyl esters updates RSS · CI watch RSS
- University of Michigan portfolio CI